Learn more about whether IDEAYA Biosciences, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...

Travere Therapeutics Inc reports fourth-quarter earnings Thursday after market close, with investors focused on the rare disease specialist’s commercial momentum following a regulatory setback that ...

• Deere (NYSE:DE) is expected to report quarterly earnings at $2.03 per share on revenue of $7.54 billion. • Lemonade (NYSE:LMND) is expected to report quarterly loss at $0.40 per share on revenue of ...

The table below is a review of notable updates that occurred in January 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Travere Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts. Travere ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Kiniksa Pharmaceuticals International, plc (KNSA) reports results for the quarter ended December 2025. While this ...

Executives from Travere Therapeutics (NASDAQ:TVTX) said the company is focused on advancing treatments in three rare diseases ...

It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...

Comfort Systems USA, Inc. , a leading provider of mechanical and electrical contracting services including heating, ...

Cars.com Inc. , an audience-driven technology company empowering the automotive industry, today announced that it expects to ...

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial ...